Sector News

Moderna swings into expansion mode, adding 6 European countries to its commercial empire

February 20, 2022
Life sciences

Moderna is spreading its wings in Europe. After setting up shop in some of the largest economies of the region last year, the mRNA specialist is expanding its commercial network to cover half a dozen more countries.

Belgium, Denmark, the Netherlands, Norway, Poland and Sweden will soon host Moderna’s commercial teams as part of the U.S. biotech’s expansion to “support the delivery of mRNA vaccines and therapeutics locally,” Moderna said Wednesday.

The teams will join Moderna’s existing 247 employees in Europe. The new hires will cover a range of functions including medical, regulatory, pricing, reimbursement, market access, government affairs and commercial operations, a Moderna spokesperson told Fierce Pharma.

The additions come after Moderna in 2021 built commercial subsidiaries in Italy, France, Germany, Spain, the U.K. and Switzerland, where Moderna’s manufacturing partner Lonza helps make the COVID-19 vaccine Spikevax.

Also on the manufacturing front, Moderna in June expanded its collaboration with Lonza, tapping a new drug substance line at the CDMO’s site in Geleen, Netherlands, to support the manufacture of the COVID shot. In Spain, local firm Rovi just inked a 10-year extension to its ongoing manufacturing deal with Moderna. And France’s Recipharm also makes drug substance for the company’s COVID vaccine for Europe.

Poland, known as the heart of Europe for its geographical positioning, is already home to the Moderna International Business Services Center, which provides supporting functions such as finance, human resources, IT and pharmacovigilance.

Besides Europe, Moderna is simultaneously planting more flags in Asia, with four new branches being planned in Hong Kong, Malaysia, Singapore and Taiwan.

In Africa, Moderna has pledged up to $500 million to build an mRNA manufacturing facility that could eventually make up to 500 million doses annually at the 50-µg dose level. The exact site remains unclear as Rwanda, Senegal and South Africa have been floated as candidates, according to Reuters.

Building a new production site can be more time-consuming than installing a commercial team. CEO Stéphane Bancel has said completion of the African project will take two to four years.

The expansion spree comes as Moderna has secured advance vaccine purchase agreements worth $18.5 billion for deliveries in 2022 along with options for another $3.5 billion as of January.

Moderna is currently in the thick of development of an omicron-specific booster. That shot could be ready by August, Bancel reportedly told Reuters.

Meanwhile, Moderna’s mRNA rival BioNTech has also been branching out geographically, with a similar ambition to become a global immunotherapy powerhouse. Besides an existing footprint in Germany and the U.S., BioNTech has also opened offices in China, Singapore and Turkey. Wednesday, the company unveiled modular factories that can be transferred in shipping containers.

by Angus Liu

Source: fiercepharma.com

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach